Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Bizzini

Showing results (121-130 of 156) with videos related to

Pageof 16
Sort By:
Cell Death and Differentiation|January 1, 1995
Are CD4 and Fas peptide identities of gp120 relevant to the molecular basis of AIDS pathogenesis?J F Zagury, V Chams, A Lachgar, et al.
Journal of Virology|January 9, 1999
Amplification of the inflammatory cellular redox state by human immunodeficiency virus type 1-immunosuppressive tat and gp160 proteinsA Lachgar, N Sojic, S Arbault, et al.
Annals of the Rheumatic Diseases|November 29, 2007
Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalphaL Delavallée, H Le Buanec, N Bessis, et al.
Annales De Microbiologie|October 1, 1978
[Investigation of the immunity status towards tetanus of a population of mechanics at the car-factory "Renault" (author's transl)]B Bizzini, P Champigneux, C Guyotjeannin, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 28, 1999
A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoidH Le Buanec, A Lachgar, B Bizzini, et al.
Cellular and Molecular Biology (Noisy-Le-Grand, France)|May 1, 1995
Evidence for an antiviral effect and interferon neutralizing capacity in human sera; variability and implications for HIV infectionL S Fall, V Chams, H Le Coq, et al.
Vaccine|January 1, 1993
Envelope protein and p18(IIIB) peptide recognized by cytotoxic T lymphocytes from humans immunized with human immunodeficiency virus envelopeA Achour, O Picard, J P Mbika, et al.
AIDS (London, England)|June 1, 1997
A placebo-controlled clinical phase I trial with combined anti-HIV-1 and anti-interferon-alpha immunizationI P Coulaud, M L Gougeon, E Gomard, et al.
The Journal of Infectious Diseases|February 1, 1983
Naturally acquired antibodies to tetanus toxin in humans and animals from the galápagos islandsR Veronesi, B Bizzini, R Focaccia, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|March 30, 1999
Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study)A Gringeri, M Musicco, P Hermans, et al.
Pageof 16

Showing results (121-130 of 156) with videos related to

Sort By:
Pageof 16
Cell Death and Differentiation|January 1, 1995
Are CD4 and Fas peptide identities of gp120 relevant to the molecular basis of AIDS pathogenesis?J F Zagury, V Chams, A Lachgar, et al.
Journal of Virology|January 9, 1999
Amplification of the inflammatory cellular redox state by human immunodeficiency virus type 1-immunosuppressive tat and gp160 proteinsA Lachgar, N Sojic, S Arbault, et al.
Annals of the Rheumatic Diseases|November 29, 2007
Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalphaL Delavallée, H Le Buanec, N Bessis, et al.
Annales De Microbiologie|October 1, 1978
[Investigation of the immunity status towards tetanus of a population of mechanics at the car-factory "Renault" (author's transl)]B Bizzini, P Champigneux, C Guyotjeannin, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 28, 1999
A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoidH Le Buanec, A Lachgar, B Bizzini, et al.
Cellular and Molecular Biology (Noisy-Le-Grand, France)|May 1, 1995
Evidence for an antiviral effect and interferon neutralizing capacity in human sera; variability and implications for HIV infectionL S Fall, V Chams, H Le Coq, et al.
Vaccine|January 1, 1993
Envelope protein and p18(IIIB) peptide recognized by cytotoxic T lymphocytes from humans immunized with human immunodeficiency virus envelopeA Achour, O Picard, J P Mbika, et al.
AIDS (London, England)|June 1, 1997
A placebo-controlled clinical phase I trial with combined anti-HIV-1 and anti-interferon-alpha immunizationI P Coulaud, M L Gougeon, E Gomard, et al.
The Journal of Infectious Diseases|February 1, 1983
Naturally acquired antibodies to tetanus toxin in humans and animals from the galápagos islandsR Veronesi, B Bizzini, R Focaccia, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|March 30, 1999
Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study)A Gringeri, M Musicco, P Hermans, et al.
Pageof 16